PREG-MS: New England MS Pregnancy Registry

Sponsor
Brigham and Women's Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT03368157
Collaborator
(none)
500
1
68
7.4

Study Details

Study Description

Brief Summary

The purpose of the study is to develop a detailed pregnancy registry of patients with Multiple Sclerosis in the New England states. Women with a diagnosis of MS that are either pregnant or actively planning to become pregnant are eligible to participate.

The study will solely take place through phone interviews. One of the study coordinator at the Partners MS Center will contact the participant for an intake phone interview where general information about the individual, their pregnancy and their MS will be collected. Thereafter the coordinator will contact the participant every 3 months for 20 minutes follow up interviews. After birth, the coordinator will collect information on the growth and development of the participant's baby. Pediatric interviews will be conducted at 2, 4, 6, 9, 12, 18, 24, 36 months. Information from the participant's neurologist and obstetrician, as well as information from the baby's pediatrician, will be made available to the study staff at regular intervals throughout the duration of the study.

Through this study, the investigators hope to learn more about the effects of MS on pregnancy and pediatric development, and about the effects of pregnancy on the course of MS.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    500 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    PREG-MS: New England MS Pregnancy Prospective Cohort Study
    Actual Study Start Date :
    Apr 7, 2017
    Anticipated Primary Completion Date :
    Jul 7, 2022
    Anticipated Study Completion Date :
    Dec 7, 2022

    Outcome Measures

    Primary Outcome Measures

    1. The relationship between EDSS and pregnancy course [9 months]

      The investigators assessed the correlation between EDSS scores and the presence of pregnancy complications, or the lack thereof.

    Secondary Outcome Measures

    1. The relationship between MS treatments and pregnancy course [9 months]

      The investigators assessed the effects of Disease modifying therapies used to treat MS and its implication on the pregnancy course.

    Other Outcome Measures

    1. The weight (pounds) of infants born to MS affected mothers [3 years]

      The evaluation of the weight in pounds of infants born to mothers affected by MS compared to standard pediatric measurements.

    2. The length (inches) of infants born to MS affected mothers [3 years]

      The evaluation of the length in inches of infants born to mothers affected by MS compared to pediatric standard measurements.

    3. The head circumference (inches) of infants born to MS affected mothers [3 years]

      The evaluation of the head circumference in inches of infants born to mothers affected by MS compared to pediatric standard measurements.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Diagnosis of Multiple Sclerosis;

    • Pregnant or actively planning to become pregnant.

    Exclusion Criteria:

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Brigham and Women's Hospital Boston Massachusetts United States 02115

    Sponsors and Collaborators

    • Brigham and Women's Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Maria Houtchens, Assistant Professor of Neurology, Brigham and Women's Hospital
    ClinicalTrials.gov Identifier:
    NCT03368157
    Other Study ID Numbers:
    • 2016P000588
    First Posted:
    Dec 11, 2017
    Last Update Posted:
    Oct 15, 2021
    Last Verified:
    Oct 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 15, 2021